RS62925B1 - Transgena murinska životinja koja proizvodi antitela - Google Patents
Transgena murinska životinja koja proizvodi antitelaInfo
- Publication number
- RS62925B1 RS62925B1 RS20220155A RSP20220155A RS62925B1 RS 62925 B1 RS62925 B1 RS 62925B1 RS 20220155 A RS20220155 A RS 20220155A RS P20220155 A RSP20220155 A RS P20220155A RS 62925 B1 RS62925 B1 RS 62925B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibody producing
- producing transgenic
- murine animal
- transgenic murine
- animal
- Prior art date
Links
- 241001529936 Murinae Species 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2008050430 | 2008-06-27 | ||
EP18183980.4A EP3456190B1 (en) | 2008-06-27 | 2009-06-29 | Antibody producing transgenic murine animal |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62925B1 true RS62925B1 (sr) | 2022-03-31 |
Family
ID=41280336
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20220155A RS62925B1 (sr) | 2008-06-27 | 2009-06-29 | Transgena murinska životinja koja proizvodi antitela |
RS20140063A RS53146B (sr) | 2008-06-27 | 2009-06-29 | Nehumani sisari koji stvaraju antitelo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20140063A RS53146B (sr) | 2008-06-27 | 2009-06-29 | Nehumani sisari koji stvaraju antitelo |
Country Status (23)
Country | Link |
---|---|
EP (6) | EP3456190B1 (sr) |
JP (6) | JP5749161B2 (sr) |
KR (5) | KR102306491B1 (sr) |
CN (3) | CN105191863B (sr) |
AU (1) | AU2009263082C1 (sr) |
CA (1) | CA2729095C (sr) |
CY (2) | CY1114830T1 (sr) |
DK (3) | DK2556747T3 (sr) |
ES (3) | ES2445193T3 (sr) |
HK (1) | HK1154463A1 (sr) |
HR (2) | HRP20220205T1 (sr) |
HU (1) | HUE057994T2 (sr) |
LT (1) | LT3456190T (sr) |
MX (1) | MX2010014542A (sr) |
NZ (1) | NZ590118A (sr) |
PL (2) | PL2147594T3 (sr) |
PT (3) | PT2147594E (sr) |
RS (2) | RS62925B1 (sr) |
RU (2) | RU2731084C2 (sr) |
SG (3) | SG10201408500RA (sr) |
SI (2) | SI2147594T1 (sr) |
WO (1) | WO2009157771A2 (sr) |
ZA (1) | ZA201009312B (sr) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
CN101537180B (zh) | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
GB2404382B (en) | 2003-07-28 | 2008-01-30 | Oxitec Ltd | Pest control |
GB2443186A (en) | 2006-10-25 | 2008-04-30 | Oxitec Ltd | Expression system for mediating alternative splicing |
LT3456190T (lt) * | 2008-06-27 | 2022-03-10 | Merus N.V. | Antikūną produkuojantis transgeninis pelių pošeimio gyvūnas |
CA2739038C (en) | 2008-09-30 | 2020-04-28 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
KR101829691B1 (ko) * | 2010-02-08 | 2018-02-19 | 리제너론 파마슈티칼스 인코포레이티드 | 일반적인 경쇄 마우스 |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
AU2013204019B2 (en) * | 2010-02-08 | 2014-02-27 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
ES2641920T3 (es) | 2010-03-31 | 2017-11-14 | Ablexis, Llc | Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos |
AU2011266843C9 (en) * | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
CA2806233C (en) | 2010-07-26 | 2021-12-07 | Trianni, Inc. | Transgenic animals and methods of use |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
EP2947151A1 (en) * | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Binding proteins comprising vl domains |
WO2013022782A1 (en) * | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
EP2758535B1 (en) * | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CA3125875A1 (en) | 2011-12-22 | 2013-06-27 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
ME03611B (me) * | 2012-02-01 | 2020-07-20 | Regeneron Pharma | Humanizovani miševi koji eksprimiraju teške lance koji sadrže vl domene |
GB2500113A (en) | 2012-03-05 | 2013-09-11 | Oxitec Ltd | Arthropod male germline gene expression system |
CN107090471A (zh) * | 2012-03-06 | 2017-08-25 | 瑞泽恩制药公司 | 共同轻链小鼠 |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
CN107361011B (zh) | 2012-03-16 | 2021-08-27 | 瑞泽恩制药公司 | 制备表达ph敏感性免疫球蛋白序列的非人动物的方法 |
HUE053310T2 (hu) | 2012-03-16 | 2021-06-28 | Regeneron Pharma | Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
CA2874846A1 (en) * | 2012-06-05 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
CN103571872B (zh) * | 2012-08-09 | 2016-11-23 | 山东国际生物科技园发展有限公司 | 一种能够表达人抗体的转基因动物的制备方法 |
ES2692951T3 (es) | 2012-09-27 | 2018-12-05 | Merus N.V. | Anticuerpos IgG biespecíficos como acopladores de células T |
GB201303932D0 (en) | 2013-03-05 | 2013-04-17 | Oxitec Ltd | Muscle actin promoter |
BR112015022034B1 (pt) * | 2013-03-13 | 2023-02-28 | Regeneron Pharmaceuticals, Inc | Método de fabricar um camundongo, e, para fabricar um anticorpo |
CA2906784C (en) | 2013-03-15 | 2023-02-28 | The Centre For Drug Research And Development | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
CN105683365A (zh) | 2013-10-01 | 2016-06-15 | 科马布有限公司 | 动物模型及治疗分子 |
EP2908626B1 (en) * | 2013-10-15 | 2016-12-07 | Regeneron Pharmaceuticals, Inc. | Humanized il-15 animals |
JP6560681B2 (ja) | 2013-12-27 | 2019-08-14 | ザイムワークス インコーポレイティド | 薬物結合体のためのスルホンアミド含有連結系 |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
CA2941077A1 (en) | 2014-02-28 | 2015-09-03 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
SG10201808225TA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
EP3119811B1 (en) | 2014-03-21 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
GB2526867A (en) * | 2014-06-05 | 2015-12-09 | Oxitec Ltd | Gene expression system |
CN113416229A (zh) | 2014-09-17 | 2021-09-21 | 酵活有限公司 | 细胞毒性和抗有丝分裂化合物、及其使用方法 |
EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
HUE042039T2 (hu) | 2015-07-10 | 2019-06-28 | Merus Nv | Humán CD3 kötõ antitest |
CA2995717A1 (en) | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
ES2865482T3 (es) | 2015-10-23 | 2021-10-15 | Merus Nv | Moléculas de unión que inhiben el crecimiento del cáncer |
WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
EP4414484A2 (en) | 2016-02-04 | 2024-08-14 | Trianni, Inc. | Enhanced production of immunoglobulins |
EP4218408A1 (en) * | 2016-06-03 | 2023-08-02 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
US11827876B2 (en) | 2016-08-12 | 2023-11-28 | Oxitec Ltd. | Self-limiting, sex-specific gene and methods of using |
MX2019003241A (es) | 2016-09-23 | 2019-11-12 | Merus Nv | Moleculas de union que modulan una actividad biologica expresada por una celula. |
CA3094322A1 (en) * | 2017-03-20 | 2018-09-27 | Washington University | Cells and methods of uses and making the same |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
JP7304815B2 (ja) | 2017-03-31 | 2023-07-07 | メルス ナムローゼ フェンノートシャップ | Erbb-2、erbb-2/erbb-3陽性腫瘍を有する個体の処置のための、erb-2及びerbb-3の細胞外部分上のエピトープに結合する抗原結合部位を含むerbb-2標的化剤及び二重特異性抗体 |
KR20200018785A (ko) | 2017-05-17 | 2020-02-20 | 메뤼스 엔.페. | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 |
US11732043B2 (en) | 2017-07-06 | 2023-08-22 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
MX2020000055A (es) | 2017-07-06 | 2020-08-06 | Merus Nv | Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3). |
SG11202000014UA (en) | 2017-07-06 | 2020-01-30 | Merus Nv | Binding molecules that modulate a biological activity expressed by a cell |
GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
CN118562014A (zh) | 2017-08-09 | 2024-08-30 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
JP2021504413A (ja) | 2017-12-01 | 2021-02-15 | メルス ナムローゼ フェンノートシャップ | 組み合わせ治療のための二重特異性抗体及びil−15の使用 |
CN116058333A (zh) * | 2017-12-05 | 2023-05-05 | 瑞泽恩制药公司 | 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途 |
TWI849895B (zh) | 2018-02-09 | 2024-07-21 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
CN112040769B (zh) | 2018-03-24 | 2023-05-16 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途 |
SG11202009036YA (en) | 2018-03-30 | 2020-10-29 | Merus Nv | Multivalent antibody |
CN108624622A (zh) * | 2018-05-16 | 2018-10-09 | 湖南艾佳生物科技股份有限公司 | 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株 |
EP3801010A4 (en) * | 2018-06-08 | 2022-02-23 | Crystal Bioscience Inc. | TRANSGENIC ANIMAL TO PRODUCE DIVERSIFIED ANTIBODIES WITH THE SAME LIGHT CHAIN I |
WO2019241692A1 (en) | 2018-06-14 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
TW202034952A (zh) | 2018-12-20 | 2020-10-01 | 荷蘭商美勒斯公司 | 用於治療疾病之CLEC12AxCD3雙特異性抗體及方法 |
WO2020132557A1 (en) | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
CN114249818A (zh) | 2018-12-31 | 2022-03-29 | 美勒斯公司 | 截短的多价多元体 |
BR112021013009A2 (pt) * | 2018-12-31 | 2021-09-14 | Merus N.V. | Domínios de ligação mistos |
CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
US20220127376A1 (en) | 2019-02-14 | 2022-04-28 | Merus N.V. | Combinations of binding moieties that bind egfr, her2 and her3 |
KR20210126699A (ko) | 2019-02-14 | 2021-10-20 | 메뤼스 엔.페. | 2개 이상의 항체를 포함하는 조성물의 제조 |
CA3125380A1 (en) | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
TW202102544A (zh) * | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
BR112021022405A2 (pt) | 2019-05-09 | 2022-04-19 | Merus Nv | Domínios variantes para multimerização de proteínas e separação das mesmas |
EP3993622A1 (en) * | 2019-07-01 | 2022-05-11 | Trianni, Inc. | Transgenic mammals and methods of use |
EP3998081A4 (en) * | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
KR20220039720A (ko) | 2019-07-30 | 2022-03-29 | 오노 야꾸힝 고교 가부시키가이샤 | 이중 특이성 항체 |
EP3772518A1 (en) | 2019-08-07 | 2021-02-10 | Merus N.V. | Modified human variable domains |
CA3151641A1 (en) | 2019-08-19 | 2021-02-25 | Merus N.V. | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor |
GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
IL293330A (en) | 2019-12-02 | 2022-07-01 | Regeneron Pharma | mhc ii peptide protein structures and uses thereof |
IL294181A (en) | 2019-12-24 | 2022-08-01 | Merus Nv | tgf-beta-rii binding proteins |
EP4097131A1 (en) | 2020-01-29 | 2022-12-07 | Merus N.V. | Means and method for modulating immune cell engaging effects |
KR20230005281A (ko) | 2020-04-24 | 2023-01-09 | 메뤼스 엔.페. | Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료 |
CN115667532A (zh) | 2020-06-02 | 2023-01-31 | 百奥赛图(北京)医药科技股份有限公司 | 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物 |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
IL303633A (en) | 2020-12-15 | 2023-08-01 | Merus Nv | Cancer treatment with an antibody that binds LGR5 and EGFR |
CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
EP4262853A1 (en) | 2020-12-16 | 2023-10-25 | Merus N.V. | Multispecific antibodies for the treatment of cancer |
CN116801907A (zh) | 2020-12-18 | 2023-09-22 | 美勒斯公司 | 抗体组合物 |
US20220195014A1 (en) | 2020-12-23 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
JP2024537091A (ja) | 2021-10-06 | 2024-10-10 | メルス ナムローゼ フェンノートシャップ | 少なくともegfrに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いegfr発現を有するがんの治療 |
CN118632872A (zh) | 2022-01-25 | 2024-09-10 | 美勒斯公司 | 用于治疗癌症的组合疗法 |
TW202337909A (zh) | 2022-03-07 | 2023-10-01 | 荷蘭商美勒斯公司 | 包括結合EGFR及cMET之抗體的組合療法 |
AU2023231050A1 (en) | 2022-03-07 | 2024-09-26 | Merus N.V. | Treatment with an antibody that binds egfr and cmet. |
GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
GB202217978D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
TW202432605A (zh) | 2022-12-23 | 2024-08-16 | 荷蘭商美勒斯公司 | 使用至少結合egfr的抗體和免疫檢查點抑制劑組合治療癌症 |
WO2024144401A1 (en) | 2022-12-28 | 2024-07-04 | Merus N.V. | Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4531078A (en) | 1983-10-27 | 1985-07-23 | Polaroid Corporation | Control circuit for electronic flash |
GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
WO1993012227A1 (en) * | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE158021T1 (de) * | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH08140528A (ja) * | 1993-12-03 | 1996-06-04 | Genpharm Internatl Inc | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5885827A (en) * | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
KR20010042329A (ko) * | 1998-03-30 | 2001-05-25 | 와일러 제임스 에프. | 코르티코트로핀 방출 인자 수용체 1-결핍 마우스 |
US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101537180B (zh) * | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
EP1439234A1 (en) * | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2005068622A2 (en) | 2004-01-20 | 2005-07-28 | Merus B.V. | Mixtures of binding proteins |
JP4487068B2 (ja) * | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法 |
JP2008538912A (ja) * | 2005-04-29 | 2008-11-13 | イナート・ファルマ | 遺伝子導入動物および組換え抗体の製造方法 |
EP2505058A1 (en) * | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
BRPI0712224B8 (pt) | 2006-06-02 | 2021-05-25 | Regeneron Pharma | anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas |
RS53340B (sr) | 2006-10-02 | 2014-10-31 | Regeneron Pharmaceuticals, Inc. | Humana antitela visokog afiniteta za humani il-4 receptor |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
LT3456190T (lt) * | 2008-06-27 | 2022-03-10 | Merus N.V. | Antikūną produkuojantis transgeninis pelių pošeimio gyvūnas |
KR101829691B1 (ko) * | 2010-02-08 | 2018-02-19 | 리제너론 파마슈티칼스 인코포레이티드 | 일반적인 경쇄 마우스 |
-
2009
- 2009-06-29 LT LTEP18183980.4T patent/LT3456190T/lt unknown
- 2009-06-29 RS RS20220155A patent/RS62925B1/sr unknown
- 2009-06-29 ES ES09075279.1T patent/ES2445193T3/es active Active
- 2009-06-29 EP EP18183980.4A patent/EP3456190B1/en active Active
- 2009-06-29 NZ NZ590118A patent/NZ590118A/xx unknown
- 2009-06-29 RS RS20140063A patent/RS53146B/sr unknown
- 2009-06-29 MX MX2010014542A patent/MX2010014542A/es active IP Right Grant
- 2009-06-29 DK DK12175544.1T patent/DK2556747T3/da active
- 2009-06-29 HR HRP20220205TT patent/HRP20220205T1/hr unknown
- 2009-06-29 SI SI200930829T patent/SI2147594T1/sl unknown
- 2009-06-29 KR KR1020207013671A patent/KR102306491B1/ko active IP Right Grant
- 2009-06-29 SG SG10201408500RA patent/SG10201408500RA/en unknown
- 2009-06-29 ES ES18183980T patent/ES2906344T3/es active Active
- 2009-06-29 RU RU2015119670A patent/RU2731084C2/ru active
- 2009-06-29 AU AU2009263082A patent/AU2009263082C1/en active Active
- 2009-06-29 PT PT90752791T patent/PT2147594E/pt unknown
- 2009-06-29 EP EP18183994.5A patent/EP3456192A1/en active Pending
- 2009-06-29 PL PL09075279T patent/PL2147594T3/pl unknown
- 2009-06-29 EP EP18183986.1A patent/EP3456191A1/en active Pending
- 2009-06-29 ES ES12175544T patent/ES2853226T3/es active Active
- 2009-06-29 PL PL18183980T patent/PL3456190T3/pl unknown
- 2009-06-29 EP EP12175544.1A patent/EP2556747B1/en active Active
- 2009-06-29 CA CA2729095A patent/CA2729095C/en active Active
- 2009-06-29 WO PCT/NL2009/050381 patent/WO2009157771A2/en active Application Filing
- 2009-06-29 CN CN201510514640.9A patent/CN105191863B/zh active Active
- 2009-06-29 KR KR1020197006239A patent/KR102112655B1/ko active IP Right Grant
- 2009-06-29 RU RU2011102962/10A patent/RU2559524C2/ru active
- 2009-06-29 SI SI200932155T patent/SI3456190T1/sl unknown
- 2009-06-29 DK DK09075279.1T patent/DK2147594T3/da active
- 2009-06-29 PT PT181839804T patent/PT3456190T/pt unknown
- 2009-06-29 CN CN200980131844.7A patent/CN102123582B/zh active Active
- 2009-06-29 KR KR1020147027471A patent/KR102261586B1/ko active IP Right Grant
- 2009-06-29 PT PT121755441T patent/PT2556747T/pt unknown
- 2009-06-29 EP EP09075279.1A patent/EP2147594B1/en active Active
- 2009-06-29 KR KR1020177015048A patent/KR101990228B1/ko active IP Right Grant
- 2009-06-29 DK DK18183980.4T patent/DK3456190T3/da active
- 2009-06-29 CN CN202011446991.8A patent/CN112481300A/zh active Pending
- 2009-06-29 SG SG10201914027VA patent/SG10201914027VA/en unknown
- 2009-06-29 SG SG10201914019YA patent/SG10201914019YA/en unknown
- 2009-06-29 JP JP2011516168A patent/JP5749161B2/ja active Active
- 2009-06-29 EP EP18184003.4A patent/EP3456193A1/en active Pending
- 2009-06-29 HU HUE18183980A patent/HUE057994T2/hu unknown
- 2009-06-29 KR KR1020117002023A patent/KR20110029156A/ko not_active Application Discontinuation
-
2010
- 2010-12-23 ZA ZA2010/09312A patent/ZA201009312B/en unknown
-
2011
- 2011-08-17 HK HK11108669.0A patent/HK1154463A1/zh unknown
-
2014
- 2014-02-12 CY CY20141100105T patent/CY1114830T1/el unknown
- 2014-02-13 HR HRP20140139AT patent/HRP20140139T1/hr unknown
-
2015
- 2015-05-12 JP JP2015097258A patent/JP2015156871A/ja active Pending
-
2017
- 2017-04-12 JP JP2017078941A patent/JP6824807B2/ja active Active
-
2020
- 2020-07-13 JP JP2020119962A patent/JP7242611B2/ja active Active
-
2022
- 2022-02-22 CY CY20221100149T patent/CY1125119T1/el unknown
- 2022-09-16 JP JP2022147656A patent/JP7439201B2/ja active Active
-
2024
- 2024-02-14 JP JP2024020295A patent/JP2024063038A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE057994T2 (hu) | Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat | |
ZA201005348B (en) | Humanized anti-c5ar antibodies | |
ZA201003850B (en) | Antigen-binding constructs | |
EP2349331A4 (en) | HUMANIZED ANTIBODIES TO IL-6 | |
ZA201102119B (en) | Improved antibody libraies | |
ZA201104468B (en) | Animal litters | |
PT2262831E (pt) | Anticorpos antiproperdina | |
GB2460160B (en) | Fishing line guide | |
GB0821100D0 (en) | Antibodies | |
EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
ZA201006099B (en) | Anti-tyrp1 antibodies | |
ZA201007976B (en) | Anti-pirb antibodies | |
EP2336311A4 (en) | ANTI-VASA ANTIBODY OF TUNA | |
GB0818356D0 (en) | Antibodies | |
HK1162585A1 (en) | Transgenic plants | |
GB0805513D0 (en) | Animal leash | |
GB0804684D0 (en) | Humanized antibody | |
GB0804687D0 (en) | Humanized antibody | |
GB0804686D0 (en) | Humanized antibody | |
GB0816323D0 (en) | Animal bedding | |
HUP0800132A2 (en) | Aquarium with brooder | |
GB0806230D0 (en) | Antibodies | |
GB0823562D0 (en) | Antibodies | |
AU2009905629A0 (en) | Transgenic non-human animals |